logo

For the Inventor, By the Inventor

Schlieren, Switzerland

Wei Xu

This inventor holds 8 USPTO granted patents and 16 published patent applications and 7 EPO patents. Top assignee: Hoffmann-La Roche Inc.. Active years: 2021-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Wei Xu. Retrieved from https://idiyas.com/inventor/wei-xu-mm7rrd27

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 

% Patents Active = 100.0

 

Average Co-Inventor Count = 6.7

ph-index = 2

Forward Citations = 8(Granted Patents)


Location History:

  • Schlieren, CH (2021 - 2024)
  • Urdorf, CH (2024)

Company Filing History:

goldMedal7 out of 5,026 
 
Hoffmann-La Roche Inc.
 patents
where one patent can have more than one assignee

Years Active: 2021-2024

Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents
1. 12098213 - Antibodies binding to HLA-A2/WT1 (2024-09-24),
2. 12038441 - CAR-T reporter based diagnostic assays to detect tumor antigens in cancer patients (2024-07-16),
3. 12000064 - Universal reporter cell assay for specificity test of novel antigen binding moieties (2024-06-04),
4. 11788205 - Car-t cell assay for specificity test of novel antigen binding moieties (2023-10-17),
5. 11718680 - Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists (2023-08-08),
6. 11513122 - Predicting response to PD-1 axis inhibitors (2022-11-29),
7. 11447558 - Bispecific antigen binding molecules comprising anti-4-1BB clone 20H4.9 (2022-09-20),
8. 11192957 - Antibodies binding to HLA-A2/WT1 (2021-12-07),

Title: Wei Xu: Innovator in Cancer Diagnostics and Therapeutics

Introduction

Wei Xu is a prominent inventor based in Schlieren, Switzerland. He has made significant contributions to the field of cancer diagnostics and therapeutics, holding a total of 8 patents. His work focuses on innovative solutions that enhance the detection and treatment of cancer.

Latest Patents

Wei Xu's latest patents include groundbreaking inventions such as antibodies binding to HLA-A2/WT1. This invention relates to antibodies that bind to HLA-A2/WT1, including bispecific antigen binding molecules designed for activating T cells. Additionally, it encompasses polynucleotides encoding such antibodies, along with vectors and host cells that comprise these polynucleotides. The invention also details methods for producing the antibodies and their application in disease treatment. Another notable patent is the CAR-T reporter based diagnostic assay, which aims to detect tumor antigens in cancer patients. This invention utilizes chimeric antigen receptor (CAR) expressing reporter cell assays to analyze patient samples, facilitating cancer diagnosis by quantifying tumor antigen expression and predicting clinical responses to immunotherapies.

Career Highlights

Throughout his career, Wei Xu has worked with esteemed companies such as Hoffmann-La Roche Inc. and F. Hoffmann-La Roche AG. His experience in these organizations has allowed him to develop and refine his innovative ideas in the field of biotechnology.

Collaborations

Wei Xu has collaborated with notable professionals in his field, including Christian Klein and Ekkehard Moessner. These collaborations have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Wei Xu is a distinguished inventor whose work in cancer diagnostics and therapeutics has the potential to significantly impact patient care. His innovative patents and collaborations reflect his commitment to advancing medical science and improving treatment outcomes for cancer patients.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…